Therapeutic Index and Safety
The therapeutic index quantifies the margin between a drug's effective and toxic doses. Narrow therapeutic index drugs require careful dosing and monitoring.
## Overview
The therapeutic index (TI) is the ratio of the toxic dose to the effective dose (TD50/ED50). It quantifies a drug's safety margin. A large TI indicates wide separation between therapeutic and toxic doses; a narrow TI means small dosing errors can cause harm or treatment failure.
## Calculating the Therapeutic Index
In preclinical studies, TI = LD50/ED50, where LD50 is the lethal dose for 50% of the population and ED50 is the effective dose for 50%. In clinical practice, the **certain safety factor** (CSF = LD1/ED99) provides a more conservative measure. The therapeutic window defines the plasma concentration range between minimum effective concentration (MEC) and minimum toxic concentration (MTC).
## Narrow Therapeutic Index Drugs
The FDA defines narrow therapeutic index (NTI) drugs as those where small differences in dose or concentration lead to serious therapeutic failures or adverse reactions. Examples include:
- **Warfarin**: INR target 2.0-3.0; subtherapeutic levels risk thrombosis, supratherapeutic levels risk hemorrhage
- **Lithium**: Therapeutic range 0.6-1.2 mEq/L; toxicity at >1.5 mEq/L causes tremor, renal damage, cardiac arrhythmias
- **Digoxin**: Therapeutic range 0.5-2.0 ng/mL; toxicity causes nausea, visual changes, fatal arrhythmias
- **Phenytoin**: Therapeutic range 10-20 mcg/mL; nonlinear pharmacokinetics make dose adjustments unpredictable
- **Theophylline**: Therapeutic range 5-15 mcg/mL; seizures and arrhythmias above 20 mcg/mL
- **Aminoglycosides**: Peak efficacy vs. trough nephrotoxicity requires careful TDM
- **Cyclosporine/Tacrolimus**: Sub-therapeutic levels risk graft rejection; excess causes nephrotoxicity
## Clinical Implications
NTI drugs typically require **therapeutic drug monitoring (TDM)** — measuring plasma drug concentrations to individualize dosing. Generic substitution for NTI drugs is controversial because bioequivalence criteria (80-125% for AUC) may allow clinically meaningful variation.
Patient factors that alter NTI drug handling include renal and hepatic impairment, age-related physiological changes, drug interactions affecting metabolism, and genetic polymorphisms in metabolizing enzymes.
## Regulatory Considerations
The FDA requires additional bioequivalence standards for certain NTI drugs, including tighter acceptance criteria and replicate crossover study designs. Some jurisdictions restrict automatic generic substitution for NTI drugs without prescriber approval.
## Strategies for Safe Use
Consistent dosing schedules, patient education about drug-food interactions, regular TDM, awareness of interacting medications, and dose adjustment protocols for organ impairment are all essential for NTI drug safety.
## Key Takeaways
- Therapeutic index = toxic dose / effective dose; higher values mean wider safety margins
- NTI drugs include warfarin, lithium, digoxin, phenytoin, and immunosuppressants
- Therapeutic drug monitoring is essential for NTI drugs
- Generic substitution of NTI drugs may produce clinically significant variability
- Patient education and consistent dosing are critical for NTI drug safety